Indapta Therapeutics
Signal active
Organization
Contact Information
Overview
Indapta Therapeutics is a privately held biotechnology company developing an NK (natural killer) cell therapy platform for the treatment of blood and solid tumor cancers.
About
Industries
Biotechnology, Medical, Biopharma
Founded
2017
Employees
1-10
Headquarters locations
San Francisco, California, United States, North America
Social
Profile Resume
Indapta Therapeutics headquartered in United States, North America, operates in the Biotechnology, Medical, Biopharma sector. The company focuses on Biotechnology and has secured $4.6B in funding across 84 round(s). With a team of 1-10 employees, Indapta Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Grant - Indapta Therapeutics, raised $4.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
7
Investors
1
Lead Investors
0
Total Funding Amount
$54.5M
Details
5
Indapta Therapeutics has raised a total of $54.5M in funding over 5 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Seed | |||
| 2017 | Seed | |||
| 2019 | Seed | |||
| 2018 | Seed |
Investors
Indapta Therapeutics is funded by 14 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Indapta Therapeutics | - | FUNDING ROUND - Indapta Therapeutics | undefined |
| Red Cedar Ventures | - | FUNDING ROUND - Red Cedar Ventures | undefined |
| Indapta Therapeutics | - | FUNDING ROUND - Indapta Therapeutics | 4.5M |
| Cancer Prevention and Research Institute of Texas | - | FUNDING ROUND - Cancer Prevention and Research Institute of Texas | 4.5M |
Recent Activity
News
Jul 17, 2024
Genetic Engineering and Biotechnology News - Harnessing the Power of g-NK Cells to Treat Hematologic Malignancies
Funding Round
May 21, 2024
Indapta Therapeutics raised $4500000 on 2024-05-21 in Grant
News
Mar 04, 2024
Business Wire - Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non ...
News
Feb 29, 2024
Business Wire - Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non ...
News
Feb 02, 2024
Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for ...
News
Jan 11, 2024
Business Wire - Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for ...